Arena Pharmaceuticals (ARNA) Must Conduct 6 Post-Marketing Studies
Tweet Send to a Friend
Up)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) must conduct 6 post-marketing studies for diet pill lorcaserin.
With Arena still halted, traders will be watching VIVUS Inc. (Nasdaq: VVUS), Orexigen (Nasdaq: OREX).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
With Arena still halted, traders will be watching VIVUS Inc. (Nasdaq: VVUS), Orexigen (Nasdaq: OREX).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Will Erickson Air-Crane (EAC) Stock Crash and Burn?
- SolarCity (SCTY), Goldman Sachs (GS) Announce $500M U.S. Rooftop Solar Lease Financing Platform
- UPDATE: Student Loan Rates Set for Change; ITT (ESI) & Corinthian (COCO) on Move
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
